

SEQUENCE LISTING

<110> DINGIVAN, CHRISTINE

<120> METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS

<130> 10271-063

<140>

<141>

<150> US 60/273,098

<151> 2001-03-02

<150> US 60/346,918

<151> 2001-10-19

<160> 13

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Mus sp.

<400> 1

Glu Tyr Tyr Met Tyr
1 5

<210> 2

<211> 17

<212> PRT

<213> Mus sp.

<400> 2

Arg Ile Asp Pro Glu Asp Gly Ser Ile Asp Tyr Val Glu Lys Phe Lys
1 5 10 15

Lys

<210> 3

<211> 9

<212> PRT

<213> Mus sp.

<400> 3

Gly Lys Phe Asn Tyr Arg Phe Ala Tyr
1 5

<210> 4

<211> 16

<212> PRT

<213> Mus sp.

<400> 4

Arg Ser Ser Gln Ser Leu Leu His Ser Ser Gly Asn Thr Leu Asn Trp
1 5 10 15

<210> 5
 <211> 7
 <212> PRT
 <213> Mus sp.

<400> 5
 Leu Val Ser Lys Leu Glu Ser
 1 5

<210> 6
 <211> 9
 <212> PRT
 <213> Mus sp.

<400> 6
 Met Gln Phe Thr His Tyr Pro Tyr Thr
 1 5

<210> 7
 <211> 347
 <212> PRT
 <213> Homo Sapiens

<400> 7
 Met Val Ala Gly Ser Asp Ala Gly Arg Ala Leu Gly Val Leu Ser Val
 1 5 10 15
 Val Cys Leu Leu His Cys Phe Gly Phe Ile Ser Cys Phe Ser Gln Gln
 20 25 30
 Ile Tyr Gly Val Val Tyr Gly Asn Val Thr Phe His Val Pro Ser Asn
 35 40 45
 Val Pro Leu Lys Glu Val Leu Trp Lys Lys Gln Lys Asp Lys Val Ala
 50 55 60
 Glu Leu Glu Asn Ser Glu Phe Arg Ala Phe Ser Ser Phe Lys Asn Arg
 65 70 75 80
 Val Tyr Leu Asp Thr Val Ser Gly Ser Leu Thr Ile Tyr Asn Leu Thr
 85 90 95
 Ser Ser Asp Glu Asp Glu Tyr Glu Met Glu Ser Pro Asn Ile Thr Asp
 100 105 110
 Thr Met Lys Phe Phe Leu Tyr Val Asp Lys Thr His Thr Cys Pro Pro
 115 120 125
 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 130 135 140
 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 145 150 155 160
 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
 165 170 175
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 180 185 190
 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
 195 200 205

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
 210 215 220
 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
 225 230 235 240
 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
 245 250 255
 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
 260 265 270
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
 275 280 285
 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
 290 295 300
 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
 305 310 315 320
 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
 325 330 335
 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 340 345

<210> 8
 <211> 5
 <212> PRT
 <213> Mus sp.

<400> 8
 Ser Tyr Asp Met Ser
 1 5

<210> 9
 <211> 7
 <212> PRT
 <213> Mus sp.

<400> 9
 Lys Val Ser Ser Gly Gly Gly
 1 5

<210> 10
 <211> 8
 <212> PRT
 <213> Mus sp.

<400> 10
 His Asn Tyr Gly Ser Phe Ala Tyr
 1 5

<210> 11
 <211> 11
 <212> PRT
 <213> Mus sp.

<400> 11
 Gln Ala Ser Gln Ser Ile Ser Asn His Leu His
 1 5 10

<210> 12
<211> 11
<212> PRT
<213> Mus sp.

<400> 12
Tyr Arg Ser Gln Ser Ile Ser Asn His Leu His
1 5 10

<210> 13
<211> 9
<212> PRT
<213> Mus sp.

<400> 13
Gln Gln Ser Gly Ser Trp Pro His Thr
1 5